BioXconomy

Latest News

EU sets new targets to boost clinical trial approvals by 2030

Oct 1, 2025

A healthcare professional is engaged in reviewing digital health records using a tablet

Pharma experts say metrics key to patient engagement success

Sep 30, 2025

Futuristic hud banner that have word acquisition on user interface screen on blue background

ACL Digital buys US CRO Symbiance to build AI-powered trials business

Sep 30, 2025

Pill bottle on table

PHIL unveils direct-to-patient 2.0 platform for pharma access and affordability

Sep 30, 2025

Acquistion written in gold on a black background

Genmab's $8bn buy validates Merus' bispecific success

Genmab's $8bn buy validates Merus' bispecific success

The Danish biotech giant is targeting late-stage head and neck cancer asset in the all-cash acquisition.

3D rendering of blue antibodies targeting a right-aligned white tumor against a black background

A tale of two epitopes: Peaks and valleys in bispecific antibody research

A tale of two epitopes: Peaks and valleys in bispecific antibody research

Oct 1, 2025

Pharmaceutical medicine capsules

Access and Channel

Pharma giants continue the patient-first revolution

Pharma giants continue the patient-first revolution

Oct 1, 2025

News from APAC

Globe showing Asia

Eyes on Asia: BMS, Mabwell Bioscience, Sovargen Eyes on Asia: BMS, Mabwell Bioscience, Sovargen

Eyes on Asia: Jiangsu Hengrui, Epigenic, US White House Eyes on Asia: Jiangsu Hengrui, Epigenic, US White House

Interviews

Colleen Tupper

Finance and Accounting

Leading the way in pharma finance: Collegium CFO Colleen Tupper shares her vision

Leading the way in pharma finance: Collegium CFO Colleen Tupper shares her vision

Naveed Masood

Access and Channel

The future of patient support: Servier’s approach to care and innovation

The future of patient support: Servier’s approach to care and innovation

Subscribe to Our Newsletters

Expert insights without the effort! Stay ahead of the curve with our free, topic-specific enewsletters delivered straight to your inbox.

AI in Life Sciences

More on life sciences AI

Lila lands $235m to accelerate AI-driven research Lila lands $235m to accelerate AI-driven research

AI meets medicine: Eli Lilly teams up with Lila Bio for radioligand therapies AI meets medicine: Eli Lilly teams up with Lila Bio for radioligand therapies

Abstract blue and tan 3D geometric shape hovering above a hole in a white surface, small orange sphere in between

AI-designed peptides ‘blew minds’ of researchers, says professor AI-designed peptides ‘blew minds’ of researchers, says professor

Text reading leukemia with pills surrounding

Charm offensive: Biotech startup raises $80m for leukemia drug Charm offensive: Biotech startup raises $80m for leukemia drug

Medical illustration of purple round clindamycin-resistant group B Streptococcus bacteria

Harnessing AI to reveal nature’s antibiotics Harnessing AI to reveal nature’s antibiotics

M&A written on wooden blocks on top of a laptop

Tempus adds seven million pathology slides with $81.25m Paige acquisition Tempus adds seven million pathology slides with $81.25m Paige acquisition

byMillie Nelson

Abstract 3D rendering of white and purple molecules against a light purple background

‘Induced proximity’: Halda Therapeutics and VantAI agree $1bn partnership for AI cancer treatment Halda Therapeutics and VantAI agree $1bn partnership for AI cancer treatment

Abstract imagery of a digital 3D face against a black background with colorful dots and lights

Cup of life or poisoned chalice? AI’s evolving role in cell and gene therapy AI’s evolving role in cell and gene therapy

AI improves design and manufacturing across drug modalities, companies say AI improves design and manufacturing across drug modalities, companies say

AI written in a brain

AI Meets longevity: Juvenescence acquires drug discovery firm Ro5 AI Meets longevity: Juvenescence acquires drug discovery firm Ro5

byMillie Nelson

From slow to RaPID: The peptide discovery process From slow to RaPID: The peptide discovery process

Creyon and Lilly pen $1bn deal to develop AI-powered oligos Creyon and Lilly pen $1bn deal to develop AI-powered oligos

More on life sciences AI